Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2
Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2
Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.